Breast cancer stage is determined by combining information about the tumor’s size, whether it has spread to lymph nodes, whether it has reached distant organs, and several biological characteristics of the cancer cells themselves. Doctors assign a stage using what’s known as the TNM system, but in the United States, the final prognostic stage also factors in tumor grade, hormone receptor status, HER2 status, and sometimes genomic test results. This means two tumors of the same size can end up at different stages depending on their biology.
The TNM System
The foundation of breast cancer staging is the TNM system, developed by the American Joint Committee on Cancer (AJCC). Each letter represents one dimension of the cancer:
- T (Tumor): Describes the size of the primary tumor and whether it has grown into nearby structures. Tumors are classified from T1 (smallest) through T4 (largest or involving the chest wall or skin). T1 tumors are 2 centimeters or smaller, T2 tumors are between 2 and 5 centimeters, and T3 tumors are larger than 5 centimeters. T4 means the tumor has grown into the chest wall or skin regardless of size.
- N (Nodes): Describes whether cancer cells have reached nearby lymph nodes, how many nodes are involved, and how large the deposits of cancer are within them. N0 means no lymph node involvement, while higher numbers indicate more extensive spread.
- M (Metastasis): Indicates whether the cancer has spread to distant parts of the body, such as bones, lungs, liver, or brain. M0 means no distant spread. M1 means the cancer has traveled to a distant site, which automatically makes it Stage IV.
Anatomic Stage vs. Prognostic Stage
The AJCC 8th edition, which is the current standard, offers two ways to assign a stage group. The anatomic stage uses only T, N, and M. The prognostic stage adds biological markers: tumor grade, estrogen receptor (ER) status, progesterone receptor (PR) status, and HER2 status. In the United States, the prognostic stage is required for all cancer reporting and is preferred for guiding patient care.
This distinction matters because biology can shift a cancer’s stage up or down compared to anatomy alone. For example, a moderately sized tumor that is ER-positive and HER2-negative tends to behave less aggressively, so it may receive a lower prognostic stage than the same-sized tumor that lacks hormone receptors. The prognostic stage better reflects how the cancer is likely to behave and respond to treatment.
How Biological Markers Are Tested
When a biopsy sample is taken, the tissue is tested for several characteristics that directly influence staging. ER and PR status are measured using a staining technique on the tissue sample. If more than 1% of the cancer cells stain positive, the tumor is considered hormone receptor positive. HER2 status is measured by similar staining or by a genetic test that looks at how many copies of the HER2 gene are present. If the result is equivocal, it’s classified as HER2-negative for staging purposes.
Tumor grade is assessed using the Nottingham system, which looks at three features of the cancer cells under a microscope: how much they resemble normal cells, how quickly they’re dividing, and how uniform they appear. Cancers are graded 1 through 3, with grade 1 being the slowest-growing and grade 3 the most aggressive. All invasive breast cancers should have ER, PR, HER2, and grade determined whenever possible.
Genomic Tests Can Lower the Stage
For certain early-stage cancers, genomic tests add another layer of information. Tests like Oncotype DX analyze the activity of 21 genes in the tumor to produce a recurrence score that estimates how likely the cancer is to return. These tests are used specifically for hormone receptor-positive, HER2-negative, node-negative tumors that are 5 centimeters or smaller.
If a genomic test returns a low-risk score, the cancer is placed in the same prognostic category as the smallest node-negative tumors, effectively Stage IA, regardless of the tumor’s actual size within that range. This result also helps determine whether chemotherapy can safely be skipped in favor of hormone therapy alone. Several validated tests, including Oncotype DX, MammaPrint, EndoPredict, and PAM50, are recognized by the AJCC for this purpose.
Clinical Stage vs. Pathological Stage
Staging happens at two distinct points. Clinical prognostic stage comes first, assigned after the initial workup: your health history, physical exam, imaging (mammography, ultrasound of the lymph nodes, and sometimes CT, MRI, or PET scans), and the biopsy results. This is the stage used to plan treatment, including whether surgery is the next step or whether chemotherapy should come first to shrink the tumor.
Pathological stage is determined after surgery, when a pathologist examines the removed tumor and any lymph nodes under a microscope. This stage is often more precise because the pathologist can measure the tumor’s exact size and count exactly how many lymph nodes contain cancer. The pathological stage can differ from the clinical stage. A tumor that appeared to involve lymph nodes on imaging might turn out to be node-negative on surgical pathology, or vice versa.
Stage 0 Through Stage IV
Stage 0 refers to ductal carcinoma in situ (DCIS), where abnormal cells are confined inside the milk ducts and have not broken through into surrounding breast tissue. It’s considered noninvasive or preinvasive and is not expected to spread in its current form, though it can progress to invasive cancer if untreated.
Stages I through III represent invasive cancers of increasing size and extent of spread. Stage I cancers are small and either haven’t reached the lymph nodes or involve only tiny deposits. Stage II includes larger tumors or those with limited lymph node involvement. Stage III covers locally advanced cancers, meaning tumors that are large, involve many lymph nodes, or have grown into the chest wall or skin, but have not spread to distant organs.
Stage IV means the cancer has metastasized to distant sites. Common locations include the bones, lungs, liver, and brain. Any tumor with M1 classification is Stage IV regardless of the tumor’s size or lymph node status. This stage is managed differently from earlier stages, with treatment focused on controlling the disease rather than curing it.
What the Stage Number Actually Reflects
The final stage number, from 0 to IV, is a composite. It rolls together tumor size, lymph node involvement, distant spread, grade, hormone receptor status, HER2 status, and potentially genomic test results into a single number. Two people with the same-sized tumor can have different stages if their tumors have different biology. A small, high-grade, hormone receptor-negative tumor may be staged higher than a larger but slow-growing, hormone receptor-positive one. The system is designed this way because prognosis and treatment decisions depend on the full picture, not just how big the tumor is.